In line, successful AD treatment with the monoclonal, IL4-Rα- blocking antibody Dupilumab has been reported to reduce absolute bacterial load and S. aureus load and to increase microbial diversity while reducing disease severity [41,42]. The gene discussed is IL4R; the disease is Alzheimer disease.